Detalhe da pesquisa
1.
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Lancet Oncol;
18(4): 446-453, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28223062
2.
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Br J Cancer;
116(11): 1402-1407, 2017 05 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28441383
3.
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Br J Cancer;
118(2): e2, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29315294
4.
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.
J Hepatocell Carcinoma;
8: 1129-1145, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34527608
5.
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
J Hematol Oncol;
8: 66, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26062823